ESG

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Iron Software funds biochar kilns in Chiang Mai, tackling an environmental crisis that threatens the city's 'mini Silicon Valley' status.

A new partnership aims to de-risk large-scale AI for critical sectors by embedding elite hardware and cybersecurity into a unified transformation model.

A new signature ice cream at the 'Greenest Show on Grass' does more than cool you down—it funds major sustainability projects across Arizona.

Weight-loss drugs offer powerful results, but what happens next? New programs aim to build lasting habits, addressing the missing link for long-term success.

A new partnership combines Edge AI processing with long-range Wi-Fi HaLow, promising to simplify and scale intelligent device deployments for enterprise.

United is set to reveal its full-year 2025 earnings, putting its ambitious growth strategy and market leadership claims to the ultimate test.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

A new joint venture between Corewell Health and Quest Diagnostics aims to reshape lab services across Michigan with a new high-tech facility and new efficiencies.

Priestly Demolition appoints an external CEO and promotes internal leaders, a strategic move to blend new expertise with its family legacy for major expansion.

DIETL's acquisition of four specialists, including a rare US freeport, signals a major consolidation in the elite world of fine art logistics.

A new health initiative aims to fight chronic disease with personalized nutrition. But can data from your body truly fix a broken food system?

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.